Subscribe To
IOBT / IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study
IOBT News
By GlobeNewsWire
September 6, 2023
IO Biotech Announces Participation in Upcoming Investor Conferences
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating more_horizontal
By Zacks Investment Research
June 15, 2023
IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study
IO Biotech (IOBT) falls 25% despite achieving the clinical milestone of enrolling 225 patients in the advanced melanoma study evaluating the IO102-IO1 more_horizontal
By GlobeNewsWire
May 30, 2023
IO Biotech to Present at the Jefferies Healthcare Conference
NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating c more_horizontal